Table 4.

Summary of the Results from the Included Studies

Study/Year	Outcome Measure	N1	Early (Within 7 Days)	N2	Delayed (8–14 Days)
Zhang et al 201418	PVR development	15	1/15	18	12/18
	Retinal reattachment		14/15		12/18
	BCVA 5/200 or better
He et al 20209	PVR development	21	3/21	25	10/25
	Retinal reattachment		17/21		15/25
	BCVA 5/200 or better		13		4
	> 1 vitrectomy		3		15
Coleman 19827	PVR development	37		22
	Retinal reattachment
	BCVA 5/200 or better		30/37		14/22
De Juan et al 19848	PVR development	43		21
	Retinal reattachment
	BCVA 5/200 or better		22/43		9/21
Ramsay et al 198516	PVR development	6		4
	Retinal reattachment		5/6		1/4
	BCVA 5/200 or better
Petrovic et al 200422	PVR development	29		14
	Retinal reattachment		27/29		12/14
	BCVA 5/200 or better
Colyer et al 200817	PVR development	3	1/3	4	3/4
	Retinal reattachment
	BCVA 5/200 or better		2/3		2/4
	Final BCVA (mean SD)
Zhang et al 201418	PVR development	15	1/15	18	12/18
	Retinal reattachment		14/15		12/18
	BCVA 5/200 or better
Ferreira et al 201519	PVR development	12	1/12	6	1/6
	Retinal reattachment		11/12		4/6
	BCVA 5/200 or better		10/12		4/6
	> 1 vitrectomy		8/12		4/6
Lin et al 201620	PVR development	4		4
	Retinal reattachment
	BCVA 5/200 or better		3/4		0/4
	> 1 vitrectomy		2		4
He et al 20209	PVR development	21	3/21	25	10/25
	Retinal reattachment		17/21		15/25
	BCVA 5/200 or better		13		4
	> 1 vitrectomy		3		15
Yu et al 201910	PVR development	20		25
	Retinal reattachment		20/20		25/25
	BCVA 5/200 or better		16/20		22/25
	> 1 vitrectomy		2		1
Chauhan et al 202221	PVR development	39	2/39	35	10/35
	Retinal reattachment
	BCVA 5/200 or better

Abbreviations: BCVA, best-corrected visual acuity; PVR, proliferative vitreoretinopathy; SD, standard deviation.